These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
204 related articles for article (PubMed ID: 29409474)
21. MALAT1 is a prognostic factor in glioblastoma multiforme and induces chemoresistance to temozolomide through suppressing miR-203 and promoting thymidylate synthase expression. Chen W; Xu XK; Li JL; Kong KK; Li H; Chen C; He J; Wang F; Li P; Ge XS; Li FC Oncotarget; 2017 Apr; 8(14):22783-22799. PubMed ID: 28187000 [TBL] [Abstract][Full Text] [Related]
22. Molecular Subgroups of Glioblastoma- an Assessment by Immunohistochemical Markers. Nagy Á; Garzuly F; Padányi G; Szűcs I; Feldmann Á; Murnyák B; Hortobágyi T; Kálmán B Pathol Oncol Res; 2019 Jan; 25(1):21-31. PubMed ID: 28948518 [TBL] [Abstract][Full Text] [Related]
23. Quiescent stem cell marker genes in glioma gene networks are sufficient to distinguish between normal and glioblastoma (GBM) samples. Mukherjee S Sci Rep; 2020 Jul; 10(1):10937. PubMed ID: 32616845 [TBL] [Abstract][Full Text] [Related]
24. Regulatory Network of PD1 Signaling Is Associated with Prognosis in Glioblastoma Multiforme. Lopes-Ramos CM; Belova T; Brunner TH; Ben Guebila M; Osorio D; Quackenbush J; Kuijjer ML Cancer Res; 2021 Nov; 81(21):5401-5412. PubMed ID: 34493595 [TBL] [Abstract][Full Text] [Related]
25. Expression and prognostic significance of CCL11/CCR3 in glioblastoma. Tian M; Chen L; Ma L; Wang D; Shao B; Wu J; Wu H; Jin Y Oncotarget; 2016 May; 7(22):32617-27. PubMed ID: 27119233 [TBL] [Abstract][Full Text] [Related]
26. Quantitative proteomics reveals the novel co-expression signatures in early brain development for prognosis of glioblastoma multiforme. Yu X; Feng L; Liu D; Zhang L; Wu B; Jiang W; Han Z; Cheng S Oncotarget; 2016 Mar; 7(12):14161-71. PubMed ID: 26895104 [TBL] [Abstract][Full Text] [Related]
27. Differential expression of miR16 in glioblastoma and glioblastoma stem cells: their correlation with proliferation, differentiation, metastasis and prognosis. Tian R; Wang J; Yan H; Wu J; Xu Q; Zhan X; Gui Z; Ding M; He J Oncogene; 2017 Oct; 36(42):5861-5873. PubMed ID: 28628119 [TBL] [Abstract][Full Text] [Related]
29. Detection of proneural/mesenchymal marker expression in glioblastoma: temporospatial dynamics and association with chromatin-modifying gene expression. Murata H; Yoshimoto K; Hatae R; Akagi Y; Mizoguchi M; Hata N; Kuga D; Nakamizo A; Amano T; Sayama T; Iihara K J Neurooncol; 2015 Oct; 125(1):33-41. PubMed ID: 26272600 [TBL] [Abstract][Full Text] [Related]
30. A 4-gene panel predicting the survival of patients with glioblastoma. Guo XX; Su J; He XF J Cell Biochem; 2019 Sep; 120(9):16037-16043. PubMed ID: 31081973 [TBL] [Abstract][Full Text] [Related]
31. miR-663 Suppresses Oncogenic Function of CXCR4 in Glioblastoma. Shi Y; Chen C; Yu SZ; Liu Q; Rao J; Zhang HR; Xiao HL; Fu TW; Long H; He ZC; Zhou K; Yao XH; Cui YH; Zhang X; Ping YF; Bian XW Clin Cancer Res; 2015 Sep; 21(17):4004-13. PubMed ID: 26023083 [TBL] [Abstract][Full Text] [Related]
32. Endothelin B receptor promotes the proliferation and immune escape of malignant gliomas. Pan DS; Feng SZ; Cao P; Li JJ Artif Cells Nanomed Biotechnol; 2018 Sep; 46(6):1230-1235. PubMed ID: 28841806 [TBL] [Abstract][Full Text] [Related]
33. Underexpression of HOXA11 Is Associated with Treatment Resistance and Poor Prognosis in Glioblastoma. Se YB; Kim SH; Kim JY; Kim JE; Dho YS; Kim JW; Kim YH; Woo HG; Kim SH; Kang SH; Kim HJ; Kim TM; Lee ST; Choi SH; Park SH; Kim IH; Kim DG; Park CK Cancer Res Treat; 2017 Apr; 49(2):387-398. PubMed ID: 27456940 [TBL] [Abstract][Full Text] [Related]
34. Prognostic Significance of TNFR-Associated Factor 1 and 2 (TRAF1 and TRAF2) in Glioblastoma. Zhang W; Sun Y; Liu L; Li Z Med Sci Monit; 2017 Sep; 23():4506-4512. PubMed ID: 28926524 [TBL] [Abstract][Full Text] [Related]
35. Multi-platform molecular profiling of a large cohort of glioblastomas reveals potential therapeutic strategies. Xiu J; Piccioni D; Juarez T; Pingle SC; Hu J; Rudnick J; Fink K; Spetzler DB; Maney T; Ghazalpour A; Bender R; Gatalica Z; Reddy S; Sanai N; Idbaih A; Glantz M; Kesari S Oncotarget; 2016 Apr; 7(16):21556-69. PubMed ID: 26933808 [TBL] [Abstract][Full Text] [Related]
36. Network-Based Transcriptome Analysis Reveals FAM3C as a Novel Potential Biomarker for Glioblastoma. Chagas PS; Chagas HIS; Naeini SE; Bhandari B; Gouron J; Malta TM; Salles ÉL; Wang LP; Yu JC; Baban B J Cell Biochem; 2024 Aug; 125(8):e30612. PubMed ID: 38923575 [TBL] [Abstract][Full Text] [Related]
37. Differential Expression and Clinical Significance of Transforming Growth Factor-Beta Isoforms in GBM Tumors. Roy LO; Poirier MB; Fortin D Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29642484 [TBL] [Abstract][Full Text] [Related]
38. Downregulation of TES by hypermethylation in glioblastoma reduces cell apoptosis and predicts poor clinical outcome. Bai Y; Zhang QG; Wang XH Eur J Med Res; 2014 Dec; 19(1):66. PubMed ID: 25498217 [TBL] [Abstract][Full Text] [Related]
39. Primate-specific miR-663 functions as a tumor suppressor by targeting PIK3CD and predicts the prognosis of human glioblastoma. Shi Y; Chen C; Zhang X; Liu Q; Xu JL; Zhang HR; Yao XH; Jiang T; He ZC; Ren Y; Cui W; Xu C; Liu L; Cui YH; Yu SZ; Ping YF; Bian XW Clin Cancer Res; 2014 Apr; 20(7):1803-13. PubMed ID: 24523440 [TBL] [Abstract][Full Text] [Related]